Allan Pereira, GI Medical Oncologist at Moffitt Cancer Center, shared on X:
“Onvansertib – FDA Fast Track
- First-line KRAS – or NRAS-mutated metastatic CRC
- Onvansertib (PLK1 inhibitor) + FOLFIRI/bevacizumab
- Randomised Phase 2 CRDF-004 trial
- Confirmed ORR 72.2% vs 42.1% with FOLFIRI/bev alone
- Median PFS not reached vs about 11 months, company-reported and immature
- A designation, not an approval
Most patients with RAS-mut mCRC, whether left- or right-sided, who have no actionable target receive first-line chemo + bevacizumab.
A 30%-point ORR gain in a randomized phase 2 trial is a real signal, and Fast Track designation should facilitate discussions with the FDA. But a designation is not an approval, ORR is not survival, and the PFS comparison is company-reported and still immature.
The question I want answered in phase 3 is whether those extra responses translate into more time for patients or enable more of them to undergo liver resection..
By the way:
Open at Moffitt (for 1L mCRC KRAS-mut):
- ROSETTA CRC-203: Pumitamig + Chemo vs Bevacizumab + Chemo in 1L Metastatic CRC (MMRp/MSS, BRAF WT) – NCT07221357
- ERAS-0015 (Pan-RAS Molecular Glue) ± Pembrolizumab or Panitumumab in RAS-Mutant Advanced Solid Tumors (AURORAS-1) – NCT06983743
- VS-7375 (Oral KRAS G12D ON/OFF Inhibitor) ± Anti-EGFR Antibody in KRAS G12D-Mutated Metastatic CRC (TARGET-D 203) – NCT07659795″
Click here for Moffitt Trial Screener:
You may also be interested in:
Allan Pereira: What Recent Research Tells Us About Early-Onset Colorectal Cancer
Allan Pereira: MASTERPLAN Shows SBRT More Than Halves Locoregional Recurrence in Pancreatic Cancer
Onvansertib Receives FDA Fast Track Designation in RAS-Mutated Colorectal Cancer
